Startups

Director, Patient Services Operations

Definium Therapeutics · Raleigh/Durham, North Carolina, United States · On-site

← All jobs
About Definium Therapeutics

Definium Therapeutics develops psychedelic-based therapeutics for psychiatric and neurological disorders. Backed by North Carolina Biotechnology Center.

About the role

The starting base pay range for this position is $180,000-$235,000, with compensation determined based on several factors including skill set, years of experience, and geographic location. Employees in this role may be entitled to additional compensation, including bonus and equity. Benefits information is listed on our Jobs Page. The Company provides competitive benefits to employees including:

What they're looking for

  • Create operational strategy for Definium Patient Services supporting a successful DT120 commercial launch
  • Manage Operational Teams including Case Managers and Leaders (i.e., Supervisors)
  • Support development and implementation of potential REMS For DT120 via partnership with internal and external partners
  • Support creation of Operational infrastructure to support overall patient journey from initial engagement through post-treatment needs
  • Develop hiring strategy for Case Management Team include role design, required skills, needed experience, and desired mindset
  • Drive hiring and onboarding process for Operation Team Members
More about this role

Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.

Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.

Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq...

Read the full posting on Definium Therapeutics's site ↗

Market Access

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.